Targeted therapy vs. DNA-adduct formation-guided design: thoughts about the future of metal-based anticancer drugs.
about
Hydrogen bonding and anticancer properties of water-soluble chiral p-cymene Ru(II) compounds with amino-oxime ligandsSynthesis and antiproliferative activity of hydroxyferrocifen hybrids against triple-negative breast cancer cells.Structure-antiproliferative activity studies on l-proline- and homoproline-4-N-pyrrolidine-3-thiosemicarbazone hybrids and their nickel(ii), palladium(ii) and copper(ii) complexes.Effect of the piperazine unit and metal-binding site position on the solubility and anti-proliferative activity of ruthenium(II)- and osmium(II)- arene complexes of isomeric indolo[3,2-c]quinoline-piperazine hybrids.Picazoplatin, an azide-containing platinum(II) derivative for target analysis by click chemistry.Mirror-image organometallic osmium arene iminopyridine halido complexes exhibit similar potent anticancer activity.Biomedical and biochemical applications of self-assembled metallacycles and metallacages.Anticancer metallodrug research analytically painting the "omics" picture--current developments and future trends.The mitochondrial apoptotic pathway is induced by Cu(II) antineoplastic compounds (Casiopeínas®) in SK-N-SH neuroblastoma cells after short exposure times.Synthesis and Structure of a Ternary Copper(II) Complex with Mixed Ligands of Diethylenetriamine and Picrate: DNA/Protein-Binding Property and In Vitro Anticancer Activity Studies.Precious metal carborane polymer nanoparticles: characterisation of micellar formulations and anticancer activity.A highly cytotoxic modified paullone ligand bearing a TEMPO free-radical unit and its copper(II) complex as potential hR2 RNR inhibitors.Organometallic anticancer agents that interfere with cellular energy processes: a subtle approach to inducing cancer cell death.Photoactive platinum(ii) β-diketonates as dual action anticancer agents.Remarkable anticancer activity of ferrocenyl-terpyridine platinum(ii) complexes in visible light with low dark toxicity.Target profiling of an antimetastatic RAPTA agent by chemical proteomics: relevance to the mode of action† †Electronic supplementary information (ESI) available: Experimental, crystallographic, biological and mass spectrometric data, full list of prTarget profiling of an antimetastatic RAPTA agent by chemical proteomics: relevance to the mode of action.Synthesis, structure, and biological active evaluation of a new cyclic tetranuclear copper(II) complex bridged both by oxamido and carboxylate groups.Synthesis, X-ray crystal structure, DNA/BSA binding, DNA cleavage and cytotoxicity studies of phenanthroline based copper(II)/zinc(II) complexes.Cisplatin Primary Complex with l-Histidine Target Revealed by IR Multiple Photon Dissociation (IRMPD) Spectroscopy.Ternary copper(II) complex: NCI60 screening, toxicity studies, and evaluation of efficacy in xenograft models of nasopharyngeal carcinoma.The antimetastatic drug NAMI-A potentiates the phenylephrine-induced contraction of aortic smooth muscle cells and induces a transient increase in systolic blood pressure.
P2860
Q28834484-881761FC-4825-4EDF-820A-406EFB391532Q30683354-4CA9510F-F005-407C-94A1-81A2F75BC68FQ31119195-DAFB8D57-FC6A-4DFC-8889-4E71418CBDB3Q33864513-709F508A-6C7F-4713-A675-CEF26296091DQ34033965-4779FA6B-949B-4314-A840-4F3DB932EA9FQ34795234-07DE39EC-E179-4C9D-87CF-0BB7F2516A4CQ37325076-2B5C06FA-FDCD-446E-BEA4-618062F64802Q38052406-7718AF0F-EF6D-4505-B4DC-EEBB6E6059C3Q38725601-9940CEBE-425E-4F2E-9614-BD9521B71343Q38912850-E1092839-3B1C-49AB-AA47-AECB0E5594B4Q38951818-D6AA5E4F-EE2C-4717-AB8A-1E4F36C90B55Q39094955-3C0E5325-13B9-4C55-B61A-7EB52EF9229CQ39229950-B61DADF6-9BBF-4575-BF4C-C8B4F403CBDFQ46506519-D2AC1C19-9E91-41BF-B7D8-AC0694D21175Q46979535-0DF03A55-15EE-43D2-A963-95EF35D28F10Q47159745-A4D8F192-B432-40AE-B8ED-E82803293F19Q47196925-EE53B138-4A9A-47CD-9B8B-4C8785701D00Q47708164-3A537346-6214-423B-A462-57CA442F5E95Q48017643-BB4BC576-79AA-41FF-BEF7-63A2C748DD95Q48171470-1CDC791E-488E-48B4-8A19-84070D892BE1Q48252600-977AC1BC-4ECB-4C39-9904-5B967ACB2742Q53503817-D479DD03-0EB3-4993-B2F1-3FA1A28202C8
P2860
Targeted therapy vs. DNA-adduct formation-guided design: thoughts about the future of metal-based anticancer drugs.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Targeted therapy vs. DNA-adduc ...... metal-based anticancer drugs.
@en
type
label
Targeted therapy vs. DNA-adduc ...... metal-based anticancer drugs.
@en
prefLabel
Targeted therapy vs. DNA-adduc ...... metal-based anticancer drugs.
@en
P2860
P50
P356
P1433
P1476
Targeted therapy vs. DNA-adduc ...... metal-based anticancer drugs.
@en
P2093
Alberta Bergamo
P2860
P304
P356
10.1039/C2DT30075C
P407
P577
2012-05-22T00:00:00Z